- Home
- KROS vs DHY Comparison
KROS vs DHY Comparison
Compare KROS & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | DHY |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.3M | 184.4M |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | KROS | DHY |
|---|---|---|
| Price | $10.75 | $1.75 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.86 | N/A |
| AVG Volume (30 Days) | 312.7K | ★ 660.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.79 | $1.74 |
| 52 Week High | $22.55 | $2.16 |
Technical Indicators
Market Signals| Indicator | KROS | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 41.08 |
| Support Level | $10.47 | $1.75 |
| Resistance Level | $12.43 | $2.05 |
| Average True Range (ATR) | 0.64 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 43.69 | 37.50 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.